Get the Stockscreener App
21.75
1.57%
-0.2691
Beam Therapeutics Inc stock is traded at $21.75, with a volume of 638.01K.
It is down -1.57% in the last 24 hours and down -16.57% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$22.02
Open:
$21.76
24h Volume:
638.01K
Relative Volume:
0.25
Market Cap:
$2.23B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-12.02
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-3.58%
1M Performance:
-16.57%
6M Performance:
+21.16%
1Y Performance:
-10.14%
1-Day Range:
$21.26
$21.93
1-Week Range:
$20.76
$24.08
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
21.75 | 2.23B | 352.57M | -143.01M | -153.40M | -1.81 |
|
ARGX
Argen X Se Adr
|
916.00 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.13 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
198.87 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
362.65 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.42 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward - Insider Monkey
Is Beam Therapeutics Inc. stock supported by innovation pipelineMarket Performance Recap & Technical Confirmation Trade Alerts - newser.com
How Beam Therapeutics Inc. stock compares to market leaders2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
How Beam Therapeutics Inc. stock valuations compare to rivalsDividend Hike & Reliable Trade Execution Plans - newser.com
BEAM Therapeutics’ SWOT analysis: genetic medicine stock faces pivotal year ahead - Investing.com
Visualizing Beam Therapeutics Inc. stock with heatmapsOil Prices & Precise Buy Zone Identification - newser.com
Published on: 2025-11-16 06:02:52 - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsOptions Play & Safe Capital Investment Plans - newser.com
Historical volatility pattern of Beam Therapeutics Inc. visualizedJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com
(BEAM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
What hedge fund activity signals for Beam Therapeutics Inc. stockJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com
How buybacks impact Beam Therapeutics Inc. stock value2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Why Beam Therapeutics Inc. stock is favored by pension fundsPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Why retail investors favor Beam Therapeutics Inc. stock2025 Analyst Calls & Weekly High Return Forecasts - newser.com
Beam Therapeutics (BEAM): Exploring Valuation as Clinical Milestones Revitalize Investor Interest - Yahoo Finance
Will Beam Therapeutics Inc. stock deliver long term returnsPortfolio Growth Summary & Consistent Return Investment Signals - newser.com
How to monitor Beam Therapeutics Inc. with trend dashboards2025 Buyback Activity & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for Beam Therapeutics Inc.Market Growth Review & Community Consensus Trade Signals - newser.com
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - The Globe and Mail
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results - MSN
15 Stocks Set to Explode in 2026 - Insider Monkey
Beam Therapeutics Stock (BEAM) Opinions on Clinical Trial Updates - Quiver Quantitative
Beam Therapeutics Bets Big On Precision Gene Editing - Finimize
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):